• Karyopharm Therapeutics Inc KPTI.OQ KPTI.O is expected to show a rise in quarterly revenue when it reports results on February 19 for the period ending December 31 2024

• The Newton Massachusetts-based company is expected to report a 3.3% increase in revenue to $34.865 million from $33.75 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.The company's guidance on January 13 2025, for the period ended December 31, was for revenue of $30.000 million.

• ​LSEG's mean analyst estimate for Karyopharm Therapeutics Inc is for a loss of 26 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Karyopharm Therapeutics Inc is $5.00​, above​ its last closing price of $0.62. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated February 17 at 13:34 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)